Authorized purpose: Computer-assisted reading aid for radiologists detecting pulmonary nodules during review of chest CT examinations in an asymptomatic population; both lungs must be in the field of view, and the original CT series must remain available.
Clinical role
Adjunctive concurrent computer-assisted detection and annotation during radiologist review; it does not replace the original CT series or establish an independent diagnosis.
Images and patients
CT/CTA · Chest; pulmonary nodules in both lungs
Key limitation
Keep in mind: The device is adjunctive and must not be used without the original CT series; the indication is chest CT in an asymptomatic population with both lungs visible. The packet does not establish a standalone clinical diagnosis or current commercial release configuration.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Computer-assisted reading aid for radiologists detecting pulmonary nodules during review of chest CT examinations in an asymptomatic population; both lungs must be in the field of view, and the original CT series must remain available.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest; pulmonary nodules in both lungs Input: Chest CT images from PACS, RIS, or directly from a CT scanner; both lungs must be in the field of view, and the packet describes DICOM input.
Who uses it?Intended users: Radiologists.
What does the software produce?Output: Pulmonary-nodule annotations, including bounding boxes and nodule characteristics such as maximum axial-plane diameter, mean diameter, and volume, viewable with the original CT series.
What is its most important limitation?Key limitation: The device is adjunctive and must not be used without the original CT series; the indication is chest CT in an asymptomatic population with both lungs visible. The packet does not establish a standalone clinical diagnosis or current commercial release configuration.
Clinical takeaway. Clinical role: Computer-assisted reading aid for radiologists detecting pulmonary nodules during review of chest CT examinations in an asymptomatic population; both lungs must be in the field of view, and the original CT series must remain available.
Evidence takeaway. Evidence from the reviewed source record: Non-clinical testing reported similar nodule-detection sensitivity and false positives per scan to the predicate but no numeric standalone sensitivity or specificity in the reviewed summary. A retrospective fully crossed MRMC reader study used 10 board-certified radiologists and 249 scans; LROC AUC improved aided versus unaided by 0.073 (95% CI 0.020-0.125), and reading time changed by -23 seconds (95% CI -42 to -3). AUC change and latency are distinct reader-study endpoints, not sensitivity or specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Computer-assisted reading aid for radiologists detecting pulmonary nodules during review of chest CT examinations in an asymptomatic population; both lungs must be in the field of view, and the original CT series must remain available.
Adjunctive concurrent computer-assisted detection and annotation during radiologist review; it does not replace the original CT series or establish an independent diagnosis.
Pulmonary-nodule annotations, including bounding boxes and nodule characteristics such as maximum axial-plane diameter, mean diameter, and volume, viewable with the original CT series.
The device is adjunctive and must not be used without the original CT series; the indication is chest CT in an asymptomatic population with both lungs visible. The packet does not establish a standalone clinical diagnosis or current commercial release configuration.
Non-clinical testing reported similar nodule-detection sensitivity and false positives per scan to the predicate but no numeric standalone sensitivity or specificity in the reviewed summary. A retrospective fully crossed MRMC reader study used 10 board-certified radiologists and 249 scans; LROC AUC improved aided versus unaided by 0.073 (95% CI 0.020-0.125), and reading time changed by -23 seconds (95% CI -42 to -3). AUC change and latency are distinct reader-study endpoints, not sensitivity or specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Non-clinical testing reported similar nodule-detection sensitivity and false positives per scan to the predicate but no numeric standalone sensitivity or specificity in the reviewed summary. A retrospective fully crossed MRMC reader study used 10 board-certified radiologists and 249 scans; LROC AUC improved aided versus unaided by 0.073 (95% CI 0.020-0.125), and reading time changed by -23 seconds (95% CI -42 to -3). AUC change and latency are distinct reader-study endpoints, not sensitivity or specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
InferRead Lung CT.AI regulatory performance study summary
DesignReader Study
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K192880
IndependenceIndependence not established
K192880
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K192880. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Chest CT images from PACS, RIS, or directly from a CT scanner; both lungs must be in the field of view, and the packet describes DICOM input.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Browser/server SaaS via URL with modules for image reception, predictive processing, storage, and display; the server can receive images from PACS, RIS, or CT scanners and users can view annotations in an existing PACS. Dedicated servers may be located at hospitals; exact current interfaces and hosting configuration are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes InferRead Lung CT.AI as Browser/Server software provided as Software as a Service via a URL, integrating algorithm logic and database in one server; dedicated servers can be located at hospitals and connected to hospital networks. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "InferRead Lung CT.AI uses the Browser/Server architecture, and is provided as Software as a Service (SaaS) via a URL." … "The system integrates algorithm logic and database in the same server to ensure the simplicity of the system". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Pulmonary-nodule annotations, including bounding boxes and nodule characteristics such as maximum axial-plane diameter, mean diameter, and volume, viewable with the original CT series.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Pulmonary-nodule annotations, including bounding boxes and nodule characteristics such as maximum axial-plane diameter, mean diameter, and volume, viewable with the original CT series.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes InferRead Lung CT.AI as Browser/Server software provided as Software as a Service via a URL, integrating algorithm logic and database in one server; dedicated servers can be located at hospitals and connected to hospital networks. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "InferRead Lung CT.AI uses the Browser/Server architecture, and is provided as Software as a Service (SaaS) via a URL." … "The system integrates algorithm logic and database in the same server to ensure the simplicity of the system". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Browser/server SaaS via URL with modules for image reception, predictive processing, storage, and display; the server can receive images from PACS, RIS, or CT scanners and users can view annotations in an existing PACS. Dedicated servers may be located at hospitals; exact current interfaces and hosting configuration are not established.
ACR AI Central provides an exact-submission model card for InferRead Lung CT.AI; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K192880 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.